Adaptimmune Therapeutics plc Asset Resilience Ratio
Adaptimmune Therapeutics plc asset resilience ratio. Adaptimmune Therapeutics plc (473A) has an Asset Resilience Ratio of 0.00% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See how many days can Adaptimmune Therapeutics plc fund operations to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Adaptimmune Therapeutics plc (2016–2024)
Asset resilience ratio of Adaptimmune Therapeutics plc from 2016 to 2024. This chart shows how Adaptimmune Therapeutics plc's Asset Resilience Ratio has changed over time. Read 473A total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Adaptimmune Therapeutics plc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of Adaptimmune Therapeutics plc.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €0.00 | 0% |
| Total Liquid Assets | €0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Adaptimmune Therapeutics plc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Adaptimmune Therapeutics plc Industry Peers by Asset Resilience Ratio
Compare Adaptimmune Therapeutics plc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
| No industry peers found with asset resilience data. | ||
Adaptimmune Therapeutics plc Asset Resilience Ratio by Year (2016–2024)
Adaptimmune Therapeutics plc asset resilience ratio by year from 2016 to 2024. The table below shows the annual Asset Resilience Ratio data for Adaptimmune Therapeutics plc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 24.58% | €60.47 Million ≈ $70.69 Million |
€245.96 Million ≈ $287.56 Million |
+23.54pp |
| 2023-12-31 | 1.04% | €2.95 Million ≈ $3.45 Million |
€282.62 Million ≈ $330.41 Million |
-28.32pp |
| 2022-12-31 | 29.36% | €96.57 Million ≈ $112.90 Million |
€328.92 Million ≈ $384.54 Million |
-17.41pp |
| 2021-12-31 | 46.78% | €219.63 Million ≈ $256.77 Million |
€469.55 Million ≈ $548.95 Million |
-22.23pp |
| 2020-12-31 | 69.01% | €311.33 Million ≈ $363.98 Million |
€451.14 Million ≈ $527.43 Million |
+47.46pp |
| 2019-12-31 | 21.55% | €39.13 Million ≈ $45.75 Million |
€181.54 Million ≈ $212.24 Million |
-27.86pp |
| 2018-12-31 | 49.42% | €136.75 Million ≈ $159.88 Million |
€276.74 Million ≈ $323.53 Million |
+5.23pp |
| 2017-12-31 | 44.18% | €124.22 Million ≈ $145.22 Million |
€281.15 Million ≈ $328.69 Million |
+34.51pp |
| 2016-12-31 | 9.68% | €22.69 Million ≈ $26.53 Million |
€234.51 Million ≈ $274.17 Million |
-- |
About Adaptimmune Therapeutics plc
Adaptimmune Therapeutics plc, a commercial-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops TECELRA ((famitresgene autoleucel or afami-cel), a genetically modified autologous T-cell immunotherapy for the treatment of adults with unresectable or metastatic synovial sarcoma; Lete-cel for the treatmen… Read more